Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiko Pharmaceutical Co's quarterly market cap
declined
from Jun. 2025 (円15,528 Mil) to Sep. 2025 (円14,975 Mil) but then
stayed the same
from Sep. 2025 (円14,975 Mil) to Dec. 2025 (円14,975 Mil).
Taiko Pharmaceutical Co's annual market cap
increased
from Dec. 2023 (円15,135 Mil) to Dec. 2024 (円16,614 Mil) but then
declined
from Dec. 2024 (円16,614 Mil) to Dec. 2025 (円14,975 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Taiko Pharmaceutical Co's Enterprise Value for Today is 円10,559 Mil.
Taiko Pharmaceutical Co (TSE:4574) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Taiko Pharmaceutical Co Market Cap Related Terms
Taiko Pharmaceutical Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Taiko Pharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiko Pharmaceutical Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Taiko Pharmaceutical Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Taiko Pharmaceutical Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Taiko Pharmaceutical Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiko Pharmaceutical Co (TSE:4574) has a Market Cap of 円13,869 Mil as of Jul. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Taiko Pharmaceutical Co and its competitors. According to the industry distribution chart, Taiko Pharmaceutical Co ranks #638 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 62.3%.
Is Taiko Pharmaceutical Co's Market Cap too high?
Taiko Pharmaceutical Co's current Market Cap is 円13,869 Mil. Based on the distribution chart, Taiko Pharmaceutical Co ranks #638 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Taiko Pharmaceutical Co has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Taiko Pharmaceutical Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Taiko Pharmaceutical Co ranks #638 out of 1024 companies for Market Cap. This places Taiko Pharmaceutical Co in the lower half of its industry. The industry median Market Cap is 219.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 219.58, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Taiko Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 219.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiko Pharmaceutical Co's current Market Cap is 円13,869 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiko Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co (TSE:4574) is currently considered Modestly Undervalued. The stock's GF Value™ is 円352.15, compared to a current price of 円276.00 — trading 21.6% below its estimated fair value. The current Market Cap is 円13,869 Mil. Taiko Pharmaceutical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Taiko Pharmaceutical Co (TSE:4574), the current Market Cap is 円13,869 Mil as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiko Pharmaceutical Co (TSE:4574) Overvalued in 2026?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円276.00 is trading 21.6% below its estimated GF Value™ of 円352.15.
GuruFocus considers Taiko Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4574:
Market Cap: 円13,869 Mil
GF Value™: 円352.15 vs. price of 円276.00 (21.6% below fair value)
No single metric tells the full story. See the TSE:4574 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
64GF Score
Get the complete analysis for TSE:4574
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4574 has been successfully added to your 
